DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Blood Cancer. According to GlobalData, Phase I drugs for Blood Cancer have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DT-2216’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DT-2216 overview

DT-2216 is under development for the treatment of solid tumor and hematologic malignancy, fibrolamellar hepatocellular carcinoma, unspecified B-cell lymphomas and T-cell lymphoma. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera), which acts by targeting VHL and BCLXL. It is administered through intravenous route and is developed using Antiapoptotic Protein Targeted Degradation (APTaD) technology.

Dialectic Therapeutics overview

Dialectic Therapeutics., is a biotechnology company that develops impactful anti-cancer drugs. The company is headquartered in United States.

For a complete picture of DT-2216’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.